More tools:Markets·Screener·Research·Chat

ARS Pharmaceuticals, Inc. Common Stock (SPRY) Financial Statements

ARS Pharmaceuticals, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00FZQGXH2
XNAS · usd
5.39▼ 0.23 (-4.09%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close5.62
Day's Range5.31 – 5.54
52-Week Range4.91 – 13.15
Volume1.1M
Avg Volume1.9M
Share Statistics
Shares Outstanding
Employees163
ExchangeXNAS
Listed2022-11-09
Share count as of August 11, 2026
Loading Income Statement…
Key questions about ARS Pharmaceuticals, Inc. Common Stock (SPRY)
What is ARS Pharmaceuticals, Inc. Common Stock's Market Cap?
ARS Pharmaceuticals, Inc. Common Stock's Market Cap is $536.0M, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's Enterprise Value?
ARS Pharmaceuticals, Inc. Common Stock's Enterprise Value is $488.9M, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's Price / Sales?
ARS Pharmaceuticals, Inc. Common Stock's Price / Sales is 4.6×, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's EV / Revenue?
ARS Pharmaceuticals, Inc. Common Stock's EV / Revenue is 4.2×, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
ARS Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
ARS Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $116.9M, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
ARS Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$215.4M, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's EBITDA?
ARS Pharmaceuticals, Inc. Common Stock's EBITDA is -$214.6M, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
ARS Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -2.17, based on as-reported figures from SEC (XBRL) filings.
What is ARS Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
ARS Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -183.6%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth+114.2%+184.5%-67.6%+1471.6%
Operating expenses:
Cost of goods sold (including related party amounts of $1,851, $866, $3,084, and $1,354, respectively)
Research and development (including related party amounts of $612, $582, $1,279, and $1,245, respectively)
Selling, general and administrative (including related party amounts of $125, $107, $261, and $231, respectively)
Total operating expenses
% of revenue282.6%365.2%247.6%263.7%
Loss from operations
% of revenue-182.6%-265.2%-147.6%-163.7%
Interest income——
Interest expense (including related party amounts of $124, $0, $246, and $0, respectively)——
Total other (expense) income, net
Net loss
% of revenue-185.2%-267.3%-147.1%-157.4%
Net loss per share, Basic
Net loss per share, Diluted